High doses of acetaminophen (APAP) result in hepatotoxicity that involves metabolic activation of the parent compound, covalent binding of the reactive intermediate N-acetyl-p-benzoquinone imine (NAPQI) to liver proteins, and depletion of hepatic glutathione. Impaired fatty acid β-oxidation has been implicated in previous studies of APAP-induced hepatotoxicity. To better understand relationships between toxicity and fatty acid β-oxidation in the liver in APAP toxicity, metabolomic assays for long chain acylcarnitines were examined in relationship to established markers of liver toxicity, oxidative metabolism, and liver regeneration in a time course study in mice. Male B6C3F1 mice were treated with APAP (200 mg/kg IP) or saline and sacrificed at 1, 2, 4, 8, 24 or 48 h after APAP. At 1 h, hepatic glutathione was depleted and APAP protein adducts were markedly increased. Alanine aminotransferase (ALT) levels were elevated at 4 and 8 h, while proliferating cell nuclear antigen (PCNA) expression, indicative of hepatocyte regeneration, was apparent at 24 h and 48 h. Elevations of palmitoyl, oleoyl and myristoyl carnitine were apparent by 2–4 h, concurrent with the onset of Oil Red O staining in liver sections. By 8 h, acylcarnitine levels were below baseline levels and remained low at 24 and 48 h. A partial least squares (PLS) model suggested a direct association of acylcarnitine accumulation in serum to APAP protein adduct and hepatic glutathione levels in mice. Overall, the kinetics of serum acylcarnitines in APAP toxicity in mice followed a biphasic pattern involving early elevation after the metabolism phases of toxicity and later depletion of acylcarnitines.
References
[1]
Larson, A.M.; Polson, J.; Fontana, R.J.; Davern, T.J.; Lalani, E.; Hynan, L.S.; Reisch, J.S.; Schiodt, F.V.; Ostapowicz, G.; Shakil, A.O.; et al. Acetaminophen-induced acute liver failure: Results of a United States multicenter, prospective study. Hepatology 2005, 42, 1364–1372, doi:10.1002/hep.20948.
[2]
Squires, R.H., Jr.; Shneider, B.L.; Bucuvalas, J.; Alonso, E.; Sokol, R.J.; Narkewicz, M.R.; Dhawan, A.; Rosenthal, P.; Rodriguez-Baez, N.; Murray, K.F.; et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J. Pediatr. 2006, 148, 652–658, doi:10.1016/j.jpeds.2005.12.051.
[3]
Mitchell, J.R.; Jollow, D.J.; Potter, W.Z.; Davis, D.C.; Gillette, J.R.; Brodie, B.B. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J. Pharmacol. Exp. Ther. 1973, 187, 185–194.
[4]
Cohen, S.D.; Khairallah, E.A. Selective protein arylation and acetaminophen-induced hepatotoxicity. Drug Metab. Rev. 1997, 29, 59–77, doi:10.3109/03602539709037573.
[5]
Roberts, D.W.; Bucci, T.J.; Benson, R.W.; Warbritton, A.R.; McRae, T.A.; Pumford, N.R.; Hinson, J.A. Immunohistochemical localization and quantification of the 3-(cystein-S-yl)-acetaminophen protein adduct in acetaminophen hepatotoxicity. Am. J. Pathol. 1991, 138, 359–371.
[6]
Hinson, J.A.; Pike, S.L.; Pumford, N.R.; Mayeux, P.R. Nitrotyrosine-protein adducts in hepatic centrilobular areas following toxic doses of acetaminophen in mice. Chem. Res. Toxicol. 1998, 11, 604–607, doi:10.1021/tx9800349.
Shankar, K.; Vaidya, V.S.; Corton, J.C.; Bucci, T.J.; Liu, J.; Waalkes, M.P.; Mehendale, H.M. Activation of PPAR-alpha in streptozotocin-induced diabetes is essential for resistance against acetaminophen toxicity. Faseb. J. 2003, 17, 1748–1750.
[11]
Manautou, J.E.; Tveit, A.; Hoivik, D.J.; Khairallah, E.A.; Cohen, S.D. Protection by clofibrate against acetaminophen hepatotoxicity in male CD-1 mice is associated with an early increase in biliary concentration of acetaminophen-glutathione adducts. Toxicol. Appl. Pharmacol. 1996, 140, 30–38, doi:10.1006/taap.1996.0194.
[12]
Manautou, J.E.; Emeigh Hart, S.G.; Khairallah, E.A.; Cohen, S.D. Protection against acetaminophen hepatotoxicity by a single dose of clofibrate: Effects on selective protein arylation and glutathione depletion. Fundam. Appl. Toxicol. 1996, 29, 229–237, doi:10.1006/faat.1996.0026.
[13]
Donthamsetty, S.; Bhave, V.S.; Mitra, M.S.; Latendresse, J.R.; Mehendale, H.M. Nonalcoholic steatohepatitic (NASH) mice are protected from higher hepatotoxicity of acetaminophen upon induction of PPARalpha with clofibrate. Toxicol. Appl. Pharmacol. 2008, 230, 327–337, doi:10.1016/j.taap.2008.02.031.
[14]
Kleemann, R.; Verschuren, L.; de Rooij, B.J.; Lindeman, J.; de Maat, M.M.; Szalai, A.J.; Princen, H.M.; Kooistra, T. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 2004, 103, 4188–4194, doi:10.1182/blood-2003-11-3791.
[15]
Chen, C.; Krausz, K.W.; Idle, J.R.; Gonzalez, F.J. Identification of novel toxicity-associated metabolites by metabolomics and mass isotopomer analysis of acetaminophen metabolism in wild-type and Cyp2e1-null mice. J. Biol. Chem. 2008, 283, 4543–4559.
[16]
Chen, C.; Krausz, K.W.; Shah, Y.M.; Idle, J.R.; Gonzalez, F.J. Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. Chem. Res. Toxicol. 2009, 22, 699–707, doi:10.1021/tx800464q.
[17]
Coen, M.; Lenz, E.M.; Nicholson, J.K.; Wilson, I.D.; Pognan, F.; Lindon, J.C. An integrated metabonomic investigation of acetaminophen toxicity in the mouse using NMR spectroscopy. Chem. Res. Toxicol. 2003, 16, 295–303, doi:10.1021/tx0256127.
[18]
Arafa, H.M. Carnitine deficiency: A possible risk factor in paracetamol hepatotoxicity. Arch. Toxicol. 2009, 83, 139–150, doi:10.1007/s00204-008-0330-x.
[19]
Yapar, K.; Kart, A.; Karapehlivan, M.; Atakisi, O.; Tunca, R.; Erginsoy, S.; Citil, M. Hepatoprotective effect of L-carnitine against acute acetaminophen toxicity in mice. Exp. Toxicol. Pathol. 2007, 59, 121–128, doi:10.1016/j.etp.2007.02.009.
James, L.P.; Letzig, L.; Simpson, P.M.; Capparelli, E.; Roberts, D.W.; Hinson, J.A.; Davern, T.J.; Lee, W.M. Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure. Drug Metab. Dispos. 2009, 37, 1779–1784, doi:10.1124/dmd.108.026195.
[22]
Muldrew, K.L.; James, L.P.; Coop, L.; McCullough, S.S.; Hendrickson, H.P.; Hinson, J.A.; Mayeux, P.R. Determination of acetaminophen-protein adducts in mouse liver and serum and human serum after hepatotoxic doses of acetaminophen using high- performance liquid chromatography with electrochemical detection. Drug Metab. Dispos. 2002, 30, 446–451, doi:10.1124/dmd.30.4.446.
James, L.P.; McCullough, S.S.; Lamps, L.W.; Hinson, J.A. Effect of N-acetylcysteine on acetaminophen toxicity in mice: Relationship to reactive nitrogen and cytokine formation. Toxicol. Sci. 2003, 75, 458–467, doi:10.1093/toxsci/kfg181.
[25]
Donahower, B.C.; McCullough, S.S.; Hennings, L.; Simpson, P.M.; Stowe, C.D.; Saad, A.G.; Kurten, R.C.; Hinson, J.A.; James, L.P. Human recombinant vascular endothelial growth factor reduces necrosis and enhances hepatocyte regeneration in a mouse model of acetaminophen toxicity. J. Pharmacol. Exp. Ther. 2010, 334, 33–43, doi:10.1124/jpet.109.163840.
[26]
Buttar, H.S.; Nera, E.A.; Downie, R.H. Serum enzyme activities and hepatic triglyceride levels in acute and subacute acetaminophen-treated rats. Toxicology 1976, 6, 9–20, doi:10.1016/0300-483X(76)90003-2.
[27]
Nakatani, T.; Ozawa, K.; Asano, M.; Ukikusa, M.; Kamiyama, Y.; Tobe, T. Differences in predominant energy substrate in relation to the resected hepatic mass in the phase immediately after hepatectomy. J. Lab. Clin. Med. 1981, 97, 887–898.
[28]
Severino, V.; Locker, J.; Ledda-Columbano, G.M.; Columbano, A.; Parente, A.; Chambery, A. Proteomic characterization of early changes induced by triiodothyronine in rat liver. J. Proteome Res. 2011, 10, 3212–3224, doi:10.1021/pr200244f.
[29]
Mitchell, J.R.; Thorgeirsson, S.S.; Potter, W.Z.; Jollow, D.J.; Keiser, H. Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin. Pharmacol. Ther. 1974, 16, 676–684.
[30]
Chaudhuri, S.; McCullough, S.S.; Hennings, L.; Letzig, L.; Simpson, P.M.; Hinson, J.A.; James, L.P. Acetaminophen hepatotoxicity and HIF-1alpha induction in mice occur without hypoxia. Toxicol. Appl. Pharmacol. 2010, 252, 211–220.
[31]
Baumgardner, J.N.; Shankar, K.; Hennings, L.; Albano, E.; Badger, T.M.; Ronis, M.J. N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis. J. Nutr. 2008, 138, 1872–1879.
[32]
Varmuza, K.; Filzmoser, P. Introduction to Multivariate Statistical Analysis in Chemometrics; Taylor & Francis-CRC Press: Boca Raton, FL, USA, 2009.
